Caplin Point Laboratories has attached a Press Release regarding grant of final approval by the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Difluprednate Ophthalmic Emulsion, 0.05% (Eye drops), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DUREZOL, from Sandoz Inc, to Subsidiary Caplin Steriles.
The above information is a part of company’s filings submitted to BSE.